Literature DB >> 1500748

Neonatal mouse model of group B streptococcal infection.

A K Rodewald1, A B Onderdonk, H B Warren, D L Kasper.   

Abstract

Neonatal mice were infected with type III group B streptococcal (GBS) strain M781 by the intraperitoneal route. Age-related susceptibility to challenge was seen within the first 5 days of life. Quantitative blood cultures demonstrated a rapid increase in bacterial numbers during the first 30 h after challenge. Infected pups showed clinical signs of septicemia, and most succumbed within 48 h of challenge. Histopathologic evaluation of the neonates showed bacterial infection within 1 day after challenge. Pregnant adult mice were given a single inoculation of serum raised in rabbits against a tetanus toxoid-conjugated type III GBS polysaccharide vaccine. This serum passively protected 100% of the offspring. This neonatal mouse model of GBS infection and protection may be suitable for study of various forms of intervention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500748     DOI: 10.1093/infdis/166.3.635

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Persistent bacteremia in rabbit fetuses despite maternal antibiotic therapy in a novel intrauterine-infection model.

Authors:  C Gras-Le Guen; T Debillon; C Toquet; A Jarry; N Winer; C Jacqueline; M F Kergueris; E Bingen; J C Roze; G Potel; D Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  A murine model for disseminated candidiasis in neonates.

Authors:  Nancy Y Tsai; Sonia S Laforce-Nesbitt; Richard Tucker; Joseph M Bliss
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

4.  Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Authors:  Francesco Doro; Sabrina Liberatori; Manuel J Rodríguez-Ortega; Cira D Rinaudo; Roberto Rosini; Marirosa Mora; Maria Scarselli; Emrah Altindis; Romina D'Aurizio; Maria Stella; Immaculada Margarit; Domenico Maione; John L Telford; Nathalie Norais; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2009-04-28       Impact factor: 5.911

5.  Deletion of repeats in the alpha C protein enhances the pathogenicity of group B streptococci in immune mice.

Authors:  C Gravekamp; B Rosner; L C Madoff
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes.

Authors:  C Gravekamp; D S Horensky; J L Michel; L C Madoff
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

7.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  L C Paoletti; M R Wessels; A K Rodewald; A A Shroff; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Cytokine-induced meningitis is dramatically attenuated in mice deficient in endothelial selectins.

Authors:  T Tang; P S Frenette; R O Hynes; D D Wagner; T N Mayadas
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  M R Wessels; L C Paoletti; A K Rodewald; F Michon; J DiFabio; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.

Authors:  M B Marques; D L Kasper; A Shroff; F Michon; H J Jennings; M R Wessels
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.